Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
2026 · 1st Quarter (Jan 1 - Mar 31)
TONIX PHARMACEUTICALS
Filed by STRATEGIC MARKETING INNOVATIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 16, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- STRATEGIC MARKETING INNOVATIONS
- Client
- TONIX PHARMACEUTICALS
- Filing UUID
- 210702ee-1574-4f22-961e-1d7fd583d04a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.